Drugs Made In America Acquisition Corp. Rights financials
$0.1249−0.08%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$136.9K | -$143.3K | -$263.7K | -$131.9K | -$330.9K |
| Net income | $1.7M | $2.0M | $2.2M | $2.3M | $1.3M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $0.06 | $0.06 | $0.07 | $0.07 | $0.05 |
| EBITDA | -$136.9K | -$143.3K | -$263.7K | -$131.9K | -$330.9K |
| Operating cash flow | -$244.6K | -$91.3K | -$56.1K | -$106.7K | -$251.2K |
| Free cash flow | -$244.6K | -$91.3K | -$56.1K | -$106.7K | -$251.2K |
| Diluted shares | 30.8M | 33.7M | 33.5M | 33.5M | 25.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.3K | $14.9K | $6.1K | $717.00 | $822.00 | $923.00 |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $350.0K | $100.0K | $0.00 | $0.00 | $0.00 | $60.9K |
| Total assets | $146.9M | $242.0M | $239.9M | $237.6M | $235.2M | $232.8M |
| Total liabilities | $9.1M | $7.4M | $7.3M | $7.4M | $7.2M | $7.2M |
| Shareholders' equity | -$7.4M | -$7.4M | -$7.3M | -$7.3M | -$7.2M | -$7.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology